Drug

Sugammadex

Approved · FDA / EMA

Emerging researchLate-stage developmentRising momentum

Also known as Bridion.

RxNorm1726988 ChEMBLCHEMBL5412674UNII361LPM2T56

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: SUGAMMADEX (ANDA213915)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX (ANDA214236)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX (ANDA214311)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX (ANDA214319)

Regulatory2026-07-28FDA

Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function After Thoracoscopic Lung Resection: A Multicenter, Randomized, Double-Blind, Controlled Trial

Clinical trial2026-06-22Results expected Q3 2026 · ClinicalTrials.gov

Effect of Neuromuscular Reversal Agents on Time for Neurological Assessment After Endotracheal Intubation in Critically Ill Patients

Clinical trial2026-06-02Results expected Q3 2027 · ClinicalTrials.gov

Comparison of Venous Tourniquet Method With Isolated Forearm Technique in Electroconvulsive Therapy in Terms of Efficacy and Safety

Clinical trial2026-05-30Primary completion · ClinicalTrials.gov

Characterizing the Heart Rate Effects From Administration of Sugammadex to Reverse Neuromuscular Blockade: An Observational Study in Patients.

Research2022-09-15Anesthesia and analgesia

Comparison of recovery after sugammadex or neostigmine reversal of rocuronium in geriatric patients undergoing spine surgery: a randomized controlled trial.

Research2021-12-01Croatian medical journal

Sugammadex for Fast-Track Surgery in Children Undergoing Cardiac Surgery: A Randomized Controlled Study.

Research2020-09-03Journal of cardiothoracic and vascular anesthesia

Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial.

Research2018-08-23British journal of anaesthesia

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Sugammadex

Aliases & brands

Bridion

RxNorm CUI

1726988

ChEMBL ID

CHEMBL5412674

UNII

361LPM2T56

Regulatory jurisdictions

emafda

Regulatory timeline

9 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2008-07-25

Latest approval

2026-07-28

Authorities

FDA · EMA

Total events

fdaU.S. Food and Drug Administration· 8 events

2026-07-28Approval

Approval: SUGAMMADEX (ANDA215260)

Evidence ↗

2026-07-28Approval

Approval: SUGAMMADEX (ANDA214236)

Evidence ↗

2026-07-28Approval

Approval: SUGAMMADEX (ANDA214311)

Evidence ↗

emaEuropean Medicines Agency· 1 event

2008-07-25Approval

Approval: Bridion (EMA)

Indication: Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced… Show full indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

170 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

170

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

154

Late-stage (III+)

122

Completed

Discontinued

PHASE DISTRIBUTIONn = 170

Early Phase 11Phase 14Phase 1 / 21Phase 210Phase 2 / 33Phase 331Phase 485Phase N / A35

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Study to Determine the Dosage of Sugammadex as a Rocuronium Reversal's Agent in Infants Younger Than 24 Months Old

Not yet recruitingPH IVUniversity Hospital, Caenn=992027

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

RecruitingPH IVThe University of Texas Medical Branch, Galvestonn=4902027

RecruitingPH IVUniversity of California, Irvinen=1282026

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

CompletedPH IVGuangzhou General Hospital of Guangzhou Military Commandn=482026

A Double-blind, Randomized, Parallel Group Study to Compare Rocuronium Reversal With Sugammadex (Bridion®) Versus Neostigmine/Glycopyrrolate and the Incidence of Urinary Retention After Elective Ambulatory Posterior Lumbar Laminectomy

CompletedPH IVUniversity of Missouri-Columbian=1182026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

CompletedPH IVGuangzhou General Hospital of Guangzhou Military Commandn=482026

CompletedPH IVUniversity of Missouri-Columbian=1182026

A Prospective Randomized Blinded Controlled Trial Comparing Clinical Outcomes in Cardiac Surgical Patients Who Receive Sugammadex vs. Placebo

CompletedPH IIIEndeavor Healthn=742025

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

CompletedPH IVClayton Petron=1842025

A Blinded Randomized Study of Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients (≥ 75 Years)

CompletedPH IVMatias Vestedn=402025

Effectiveness of Sugammadex Versus Neostigmine on the Reversal of Rocuronium-induced Neuromuscular Blockade in Patients With Myasthenia Gravis After Thoracoscopic Thymectomy: A Multicenter Randomized Controlled Trial

CompletedN/ABeijing Tongren Hospitaln=622025

Research activity

24 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20082022

Most influential

Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.

Anesthesiology · 2008 · 231 cites

Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block.

British journal of anaesthesia · 2014 · 192 cites

Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.

European journal of anaesthesiology · 2010 · 157 cites

Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.

British journal of anaesthesia · 2015 · 150 cites

Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.

Anesthesiology · 2009 · 131 cites

Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.

Anesthesia and analgesia · 2010 · 107 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Sugammadex sodium

Frequently co-studied with Sugammadex in the research literature.

2 shared papers

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.